<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               17. PATIENT COUNSELING INFORMATION<BR>               <BR>                  <BR>                     See 17.8 for FDA-Approved Patient Labeling.<BR>                  <BR>               <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     17.1 Hepatotoxicity<BR>                     <BR>                        Inform patients that symptoms of weakness, fatigue, anorexia, nausea, vomiting, abdominal pain (especially RUQ abdominal pain), jaundice, dark urine, generalized pruritus, and bleeding diathesis, especially in combination with fever and rash, should be reported immediately [see Warnings and Precautions (5)].<BR>                        <BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     17.2 Gastrointestinal Effects<BR>                     <BR>                        Inform patients that nausea, diarrhea, vomiting, and constipation are the most commonly reported gastrointestinal adverse events occurring in patients who received XALKORI. Supportive care for gastrointestinal adverse events requiring treatment may include standard anti-emetic and/or anti-diarrheal or laxative medications [see Adverse Reactions (6)].<BR>                        <BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     17.3 Visual Effects<BR>                     <BR>                        Inform patients that visual changes such as perceived flashes of light, blurry vision, light sensitivity, and floaters are commonly reported adverse events. These events began most commonly during the first two weeks of treatment. Advise patients to report flashes or floaters to their physicians [see Adverse Reactions (6)].<BR>                        <BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     17.4 Effects on Ability to Drive and Use Machines<BR>                     <BR>                        No studies on the effect of XALKORI on the ability to drive and use machines have been performed. However, advise patients to exercise caution when driving or operating machinery due to the risk of developing a vision disorder, dizziness, or fatigue while taking XALKORI [see Adverse Reactions (6)].<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     17.5 Concomitant Medications<BR>                     <BR>                        Advise patients to inform their health care providers of all concomitant medications, including prescription medicines, over-the-counter drugs, vitamins, and herbal products [see Drug Interactions (7)].<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     17.6 Instructions for Taking XALKORI<BR>                     <BR>                        Advise patients to take XALKORI exactly as prescribed, not to change their dose or to stop taking XALKORI unless they are told to do so by their doctor. Take XALKORI with or without food. Swallow XALKORI capsules whole.<BR>                        Advise patients to keep XALKORI in the original container. Do not crush, dissolve, or open capsules.<BR>                        Inform patients to avoid grapefruit or grapefruit juice while taking XALKORI.<BR>                        If a patient misses a dose, advise the patient to take it as soon as remembered unless it is less than 6 hours until the next dose, in which case, advise the patient not to take the missed dose. Advise patients not to take two doses at the same time to make up for a missed dose.<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     17.7 Pregnancy and Nursing<BR>                     <BR>                        Inform patients of childbearing potential to use adequate contraceptive methods during therapy and for at least 90 days after completing therapy. Advise patients to inform their doctor if they or their partners are pregnant or think they may be pregnant. Also advise patients not to breastfeed while taking XALKORI.<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     17.8 FDA-Approved Patient Labeling<BR>                     <BR>                        LAB-0440-5.0<BR>February 2012<BR>                     <BR>                     <BR>                  <BR>               <BR>            <BR>         </P></DIV></HTML>